🇺🇸 FDA
Patent

US 10696718

Compstatin analogs for treatment of neuropathic pain

granted A61KA61K38/10A61K38/12

Quick answer

US patent 10696718 (Compstatin analogs for treatment of neuropathic pain) held by Apellis Pharmaceuticals, Inc. expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Apellis Pharmaceuticals, Inc.
Grant date
Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K38/10, A61K38/12, A61K38/16, A61K45/06